Loading…
Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study
The optimal treatment for Graves' disease in children is controversial. Antithyroid medications are often used initially, but many children eventually require alternative therapies. We evaluated predictors of remission after 2 years of antithyroid medication use. We prospectively studied childr...
Saved in:
Published in: | Pediatrics (Evanston) 2008-03, Vol.121 (3), p.e481-e488 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3 |
---|---|
cites | cdi_FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3 |
container_end_page | e488 |
container_issue | 3 |
container_start_page | e481 |
container_title | Pediatrics (Evanston) |
container_volume | 121 |
creator | Glaser, Nicole S Styne, Dennis M Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group |
description | The optimal treatment for Graves' disease in children is controversial. Antithyroid medications are often used initially, but many children eventually require alternative therapies. We evaluated predictors of remission after 2 years of antithyroid medication use.
We prospectively studied children who had Graves' disease and were treated with antithyroid medications. We compared children who achieved remission after 2 years with those who had persistent disease to determine which variables were associated with remission; multiple logistic regression and binary recursive partitioning analyses were used to evaluate interactions among predictive variables.
Of 51 children who completed the study, 15 (29%) achieved remission. Children who achieved remission had lower thyroid hormone concentrations at presentation than those with persistent disease (free thyroxine: 6.17 +/- 3.10 vs 9.86 +/- 7.54 ng/dL; total triiodothyronine: 431 +/- 175 vs 561 +/- 225 ng/dL). Children who achieved remission were also more likely to be euthyroid within 3 months of initiating propylthiouracil (82% vs 29%). Binary recursive partitioning analysis identified rapid achievement of euthyroid status after initiation of propylthiouracil, lower initial triiodothyronine, and older age as significant predictors of remission. CONCLUSIONS; Thyroid hormone concentrations at diagnosis, age, and initial response to propylthiouracil can be used to stratify patients according to the likelihood of remission after 2 years of antithyroid medication use. These data provide a useful guide for clinical decision-making regarding Graves' disease in children. |
doi_str_mv | 10.1542/peds.2007-1535 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70360397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70360397</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3</originalsourceid><addsrcrecordid>eNpdkc1v1DAQxS0EotvClSOyOJQL2frbTm_VUgrSIqoC4mh57Unjkk22tlPU_76JdiUQp5nDb97Mm4fQG0qWVAp2toOQl4wQXVHJ5TO0oKQ2lWBaPkcLQjitBCHyCB3nfEcIEVKzl-iIGqZ0resFitcJQvQl9re4tIDX8Td0sR2GgIcG38A25hyHHscer9rYhQQ9_hVLi6-Se4D8Hn-MGVyGc3yBr9OQdzBpPcAH_HXsSvTQF0j4exnD4yv0onFdhteHeoJ-frr8sfpcrb9dfVldrCvPFSmVU8EzYYzUSgRJN7o2AKLZOAZMBOUcJ15Izx31TAemjCKydhultGlA-cBP0Oled5eG-xFysZMHD13nehjGbDWZ9vBaT-C7_8C7YUz9dJtlzHCmuJETtNxDfjKXEzR2l-LWpUdLiZ0TsHMCdk7AzglMA28PquNmC-Evfnj5BJztgTbetn9iglkhupKiz_-0lFHLLQhD-RNtp5K_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>228326385</pqid></control><display><type>article</type><title>Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study</title><source>EZB Electronic Journals Library</source><creator>Glaser, Nicole S ; Styne, Dennis M ; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creator><creatorcontrib>Glaser, Nicole S ; Styne, Dennis M ; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group ; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group ; for the Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study Group</creatorcontrib><description>The optimal treatment for Graves' disease in children is controversial. Antithyroid medications are often used initially, but many children eventually require alternative therapies. We evaluated predictors of remission after 2 years of antithyroid medication use.
We prospectively studied children who had Graves' disease and were treated with antithyroid medications. We compared children who achieved remission after 2 years with those who had persistent disease to determine which variables were associated with remission; multiple logistic regression and binary recursive partitioning analyses were used to evaluate interactions among predictive variables.
Of 51 children who completed the study, 15 (29%) achieved remission. Children who achieved remission had lower thyroid hormone concentrations at presentation than those with persistent disease (free thyroxine: 6.17 +/- 3.10 vs 9.86 +/- 7.54 ng/dL; total triiodothyronine: 431 +/- 175 vs 561 +/- 225 ng/dL). Children who achieved remission were also more likely to be euthyroid within 3 months of initiating propylthiouracil (82% vs 29%). Binary recursive partitioning analysis identified rapid achievement of euthyroid status after initiation of propylthiouracil, lower initial triiodothyronine, and older age as significant predictors of remission. CONCLUSIONS; Thyroid hormone concentrations at diagnosis, age, and initial response to propylthiouracil can be used to stratify patients according to the likelihood of remission after 2 years of antithyroid medication use. These data provide a useful guide for clinical decision-making regarding Graves' disease in children.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2007-1535</identifier><identifier>PMID: 18267979</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>United States: Am Acad Pediatrics</publisher><subject>Adolescent ; Age Factors ; Antithyroid Agents - administration & dosage ; Child ; Children & youth ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Graves Disease - diagnosis ; Graves Disease - drug therapy ; Hormones ; Humans ; Logistic Models ; Male ; Multivariate Analysis ; Pediatrics ; Predictive Value of Tests ; Propylthiouracil - administration & dosage ; Prospective Studies ; Risk Assessment ; Severity of Illness Index ; Sex Factors ; Studies ; Thyroid diseases ; Thyroid Function Tests ; Treatment Outcome</subject><ispartof>Pediatrics (Evanston), 2008-03, Vol.121 (3), p.e481-e488</ispartof><rights>Copyright American Academy of Pediatrics Mar 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3</citedby><cites>FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18267979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glaser, Nicole S</creatorcontrib><creatorcontrib>Styne, Dennis M</creatorcontrib><creatorcontrib>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creatorcontrib><creatorcontrib>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creatorcontrib><creatorcontrib>for the Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study Group</creatorcontrib><title>Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>The optimal treatment for Graves' disease in children is controversial. Antithyroid medications are often used initially, but many children eventually require alternative therapies. We evaluated predictors of remission after 2 years of antithyroid medication use.
We prospectively studied children who had Graves' disease and were treated with antithyroid medications. We compared children who achieved remission after 2 years with those who had persistent disease to determine which variables were associated with remission; multiple logistic regression and binary recursive partitioning analyses were used to evaluate interactions among predictive variables.
Of 51 children who completed the study, 15 (29%) achieved remission. Children who achieved remission had lower thyroid hormone concentrations at presentation than those with persistent disease (free thyroxine: 6.17 +/- 3.10 vs 9.86 +/- 7.54 ng/dL; total triiodothyronine: 431 +/- 175 vs 561 +/- 225 ng/dL). Children who achieved remission were also more likely to be euthyroid within 3 months of initiating propylthiouracil (82% vs 29%). Binary recursive partitioning analysis identified rapid achievement of euthyroid status after initiation of propylthiouracil, lower initial triiodothyronine, and older age as significant predictors of remission. CONCLUSIONS; Thyroid hormone concentrations at diagnosis, age, and initial response to propylthiouracil can be used to stratify patients according to the likelihood of remission after 2 years of antithyroid medication use. These data provide a useful guide for clinical decision-making regarding Graves' disease in children.</description><subject>Adolescent</subject><subject>Age Factors</subject><subject>Antithyroid Agents - administration & dosage</subject><subject>Child</subject><subject>Children & youth</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graves Disease - diagnosis</subject><subject>Graves Disease - drug therapy</subject><subject>Hormones</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Multivariate Analysis</subject><subject>Pediatrics</subject><subject>Predictive Value of Tests</subject><subject>Propylthiouracil - administration & dosage</subject><subject>Prospective Studies</subject><subject>Risk Assessment</subject><subject>Severity of Illness Index</subject><subject>Sex Factors</subject><subject>Studies</subject><subject>Thyroid diseases</subject><subject>Thyroid Function Tests</subject><subject>Treatment Outcome</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNpdkc1v1DAQxS0EotvClSOyOJQL2frbTm_VUgrSIqoC4mh57Unjkk22tlPU_76JdiUQp5nDb97Mm4fQG0qWVAp2toOQl4wQXVHJ5TO0oKQ2lWBaPkcLQjitBCHyCB3nfEcIEVKzl-iIGqZ0resFitcJQvQl9re4tIDX8Td0sR2GgIcG38A25hyHHscer9rYhQQ9_hVLi6-Se4D8Hn-MGVyGc3yBr9OQdzBpPcAH_HXsSvTQF0j4exnD4yv0onFdhteHeoJ-frr8sfpcrb9dfVldrCvPFSmVU8EzYYzUSgRJN7o2AKLZOAZMBOUcJ15Izx31TAemjCKydhultGlA-cBP0Oled5eG-xFysZMHD13nehjGbDWZ9vBaT-C7_8C7YUz9dJtlzHCmuJETtNxDfjKXEzR2l-LWpUdLiZ0TsHMCdk7AzglMA28PquNmC-Evfnj5BJztgTbetn9iglkhupKiz_-0lFHLLQhD-RNtp5K_</recordid><startdate>20080301</startdate><enddate>20080301</enddate><creator>Glaser, Nicole S</creator><creator>Styne, Dennis M</creator><creator>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creator><general>Am Acad Pediatrics</general><general>American Academy of Pediatrics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>20080301</creationdate><title>Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study</title><author>Glaser, Nicole S ; Styne, Dennis M ; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Age Factors</topic><topic>Antithyroid Agents - administration & dosage</topic><topic>Child</topic><topic>Children & youth</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graves Disease - diagnosis</topic><topic>Graves Disease - drug therapy</topic><topic>Hormones</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Multivariate Analysis</topic><topic>Pediatrics</topic><topic>Predictive Value of Tests</topic><topic>Propylthiouracil - administration & dosage</topic><topic>Prospective Studies</topic><topic>Risk Assessment</topic><topic>Severity of Illness Index</topic><topic>Sex Factors</topic><topic>Studies</topic><topic>Thyroid diseases</topic><topic>Thyroid Function Tests</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glaser, Nicole S</creatorcontrib><creatorcontrib>Styne, Dennis M</creatorcontrib><creatorcontrib>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creatorcontrib><creatorcontrib>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creatorcontrib><creatorcontrib>for the Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glaser, Nicole S</au><au>Styne, Dennis M</au><au>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</au><aucorp>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</aucorp><aucorp>for the Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>2008-03-01</date><risdate>2008</risdate><volume>121</volume><issue>3</issue><spage>e481</spage><epage>e488</epage><pages>e481-e488</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>The optimal treatment for Graves' disease in children is controversial. Antithyroid medications are often used initially, but many children eventually require alternative therapies. We evaluated predictors of remission after 2 years of antithyroid medication use.
We prospectively studied children who had Graves' disease and were treated with antithyroid medications. We compared children who achieved remission after 2 years with those who had persistent disease to determine which variables were associated with remission; multiple logistic regression and binary recursive partitioning analyses were used to evaluate interactions among predictive variables.
Of 51 children who completed the study, 15 (29%) achieved remission. Children who achieved remission had lower thyroid hormone concentrations at presentation than those with persistent disease (free thyroxine: 6.17 +/- 3.10 vs 9.86 +/- 7.54 ng/dL; total triiodothyronine: 431 +/- 175 vs 561 +/- 225 ng/dL). Children who achieved remission were also more likely to be euthyroid within 3 months of initiating propylthiouracil (82% vs 29%). Binary recursive partitioning analysis identified rapid achievement of euthyroid status after initiation of propylthiouracil, lower initial triiodothyronine, and older age as significant predictors of remission. CONCLUSIONS; Thyroid hormone concentrations at diagnosis, age, and initial response to propylthiouracil can be used to stratify patients according to the likelihood of remission after 2 years of antithyroid medication use. These data provide a useful guide for clinical decision-making regarding Graves' disease in children.</abstract><cop>United States</cop><pub>Am Acad Pediatrics</pub><pmid>18267979</pmid><doi>10.1542/peds.2007-1535</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0031-4005 |
ispartof | Pediatrics (Evanston), 2008-03, Vol.121 (3), p.e481-e488 |
issn | 0031-4005 1098-4275 |
language | eng |
recordid | cdi_proquest_miscellaneous_70360397 |
source | EZB Electronic Journals Library |
subjects | Adolescent Age Factors Antithyroid Agents - administration & dosage Child Children & youth Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies Graves Disease - diagnosis Graves Disease - drug therapy Hormones Humans Logistic Models Male Multivariate Analysis Pediatrics Predictive Value of Tests Propylthiouracil - administration & dosage Prospective Studies Risk Assessment Severity of Illness Index Sex Factors Studies Thyroid diseases Thyroid Function Tests Treatment Outcome |
title | Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A46%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicting%20the%20Likelihood%20of%20Remission%20in%20Children%20With%20Graves'%20Disease:%20A%20Prospective,%20Multicenter%20Study&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Glaser,%20Nicole%20S&rft.aucorp=Organization%20of%20Pediatric%20Endocrinologists%20of%20Northern%20California%20Collaborative%20Graves'%20Disease%20Study%20Group&rft.date=2008-03-01&rft.volume=121&rft.issue=3&rft.spage=e481&rft.epage=e488&rft.pages=e481-e488&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.2007-1535&rft_dat=%3Cproquest_cross%3E70360397%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=228326385&rft_id=info:pmid/18267979&rfr_iscdi=true |